Thus, although a strong relationship between neurodegenerative disease progression and LCN2 levels in the CNS and blood have been reported, clinicians should use caution when using LCN2 levels as a clinical indicator of neurodegenerative disease progression. This evidence concerns the gene LCN2 and neurodegenerative disease.